The CFit Study
Details
- Therapeutic approach
- Other
- Trial status
- Closed with results Participating Centres
- Trials Tracker ID
- TT001811
- Last updated
- 08/04/2020
A CFit Study: To what extent does inflammation, oxidative stress, nitric oxide bioavailability and microvascular endothelial dysfunction influence the aerobic exercise function of individuals with cystic fibrosis, with and without established diabetes (The CFit Study)
Study detailsA CFit Study: To what extent does inflammation, oxidative stress, nitric oxide bioavailability and microvascular endothelial dysfunction influence the aerobic exercise function of individuals with cystic fibrosis, with and without established diabetes (The CFit Study)
- Phase
- Not applicable
- Recruitment target
- 0
- CF sponsor
- University of Portsmouth
- CF sponsor type
- Academic
Who can take part?
- Age range
- 12 years and older
- Including people
Established CFRD in accordance with the most recent American Diabetes Association positional statement. This statement recommends CFRD is diagnosed using a 2 hour OGTT. However, the present study will also include those based on fasting plasma glucose and glycated hemoglobin levels, when symptoms of diabetes are also present:2 hour OGTT plasma glucose ≥ 200 mg.dL-1.Fasting plasma glucose ≥ 126 mg.dL-1 (7.0 mmol.L-1).Glycated hemoglobin ≥ 48 mmol/mol
- Excluding people
Any non-pulmonary conditions that may impair exercise ability, such as musculoskeletal disorders (arthritis, joint or muscle disease) and cardiovascular disease (congenital heart disease or cardiomyopathy).
Unstable co-morbid asthma (daily pulmonary function variability of >20%).